Skip to main content
Smart Investors Daily
Pharmagen, Inc. logo

OTC · PHRX

Pharmagen, Inc.

Healthcare · Medical - Distribution

$0.00

Up+$0.00 (+0.00%)

Updated Aug 16, 2026, 12:45 PM

SID Score

4.0/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
5.17K
P/E ratio
-0
Dividend yield
0.00%
52-week range
— – —
Volume
2.4K
Avg. volume
17.09K

Price performance

PHRX price history

1M range · 0 trading sessions · Daily adjusted prices

PHRX does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest PHRX news

The latest Smart Investors Daily articles mentioning PHRX.

PHRX research

Overview

Company profile and research snapshot.

Company profile

PHARMAGEN INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
Open full forecast

News briefing

No generated briefing is available yet.

newsfilecorp.com · Oct 31, 2025

PharmaDrug Announces Debt Restructuring

Toronto, Ontario--(Newsfile Corp. - October 31, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has agreed to issue $445,686 principal amount of secured convertible debentures to two current holders of the Company's secured convertible debentures that were past their maturity date. Each Debenture will mature on October 13, 2026 and will be convertible into common shares at a price of $0.05 (subject to adjustment).

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.